Herein, through a prospective bicentric study, we aimed to assess the benefits of the early diagnosis of EGFR mutations in the therapeutic initiation in 225 patients with NSCLC, and thus define this benefit from the patient’s point of view by evaluating delays in pathology processing and in initiation of therapy. Here, EGFR is linked to non-small cell lung carcinoma.